Herrick Siegel, MD


Areas of Interest
musculoskeletal oncologic, metabolic, and arthritic disorders, limb salvage procedures in pediatric and adult patients


Dr. Siegel received his MD degree from New York University (NYU) School of Medicine. He completed an orthopedic surgery residency at the University of Southern California (USC), Los Angeles, and an orthopedic oncology and adult reconstruction fellowship at the Mayo Clinic, Rochester, Minnesota. He joined the UAB faculty in 2002 and since has developed one of the busiest and national renowned joint replacement and oncology practices in the Southeast. He is an expert in the direct anterior hip approach for total hip replacement surgery. He has a referral base from Florida, Mississippi, the gulf coast, Georgia and Alabama reach as far south as Mobile. Additionally, Dr. Siegel manages the total joint replacement needs of patients with Von Willebrands Disease, sickle cell anemia and hereditary and developmental dysplasias. He is involved with the Surgical Site Infection Committee, which was developed to serve as a leadership group to reduce hospital acquired infections and involved with a chronic anemia program that seeks to reduce the need for blood transfusions. This group has reduced the need for blood transfusion from primary joint zero to nearly 0. This program has attracted many Jehovah's Witness patients who are able to safely undergo hip and knee surgery without the need for transfusion.

Dr. Siegel is involved with implant and instrument development and teaches the direct anterior hip approach nationally and internationally. His clinical and research interests center on the treatment of musculoskeletal oncologic, metabolic, and arthritic disorders. Specifically, his clinical focus is on improving techniques for limb salvage procedures in pediatric and adult patients. Dr. Siegel has advanced training in the management of bone loss secondary to metastatic disease, primary bone malignancy, and revision total joint surgery. His basic science interests involve the molecular basis of malignant bone tumors and developing a tool using microarray technology to predict the response to chemotherapy of individual tumors.


Medical School
New York University

USC Medical Center

Mayo Clinic


Campus Address
HGLD 202

(205) 930-8339